title: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
abstract: OBJECTIVE
  To compare the long-term survival of patients with isolated and resectable peritoneal carcinomatosis (PC) in comparable groups of patients treated with systemic chemotherapy containing oxaliplatin or irinotecan or by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
  
  
  METHODS
  All patients with gross PC from colorectal adenocarcinoma who had undergone cytoreductive surgery plus HIPEC from 1998 to 2003 were evaluated. The standard group was constituted by selecting patients with colorectal PC treated with palliative chemotherapy during the same period, but who had not benefited from HIPEC because the technique was unavailable in the center at that time.
  
  
  RESULTS
  Forty-eight patients were retrospectively included in the standard group and were compared with 48 patients who had undergone HIPEC and were evaluated prospectively. All characteristics were comparable except age and tumor differentiation. There was no difference in systemic chemotherapy, with a mean of 2.3 lines per patient. Median follow-up was 95.7 months in the standard group versus 63 months in the HIPEC group. Two-year and 5-year overall survival rates were 81% and 51% for the HIPEC group, respectively, and 65% and 13% for the standard group, respectively. Median survival was 23.9 months in the standard group versus 62.7 months in the HIPEC group (P < .05, log-rank test).
  
  
  CONCLUSIONS
  Patients with isolated, resectable PC achieve a median survival of 24 months with modern chemotherapies, but only surgical cytoreduction plus HIPEC is able to prolong median survival to roughly 63 months, with a 5-year survival rate of 51%.
authors.affiliation: Département de Chirurgie Carcinologique, Institut Gustave Roussy, Villejuif, France. elias@igr.fr
authors.forename: Dominique
authors.initials: D
authors.lastname: Elias
authors.forename: Jérémie H
authors.initials: JH
authors.lastname: Lefevre
authors.forename: Julie
authors.initials: J
authors.lastname: Chevalier
authors.forename: Antoine
authors.initials: A
authors.lastname: Brouquet
authors.forename: Frédéric
authors.initials: F
authors.lastname: Marchal
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Classe
authors.forename: Gwenaël
authors.initials: G
authors.lastname: Ferron
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Guilloit
authors.forename: Pierre
authors.initials: P
authors.lastname: Meeus
authors.forename: Diane
authors.initials: D
authors.lastname: Goéré
authors.forename: Julia
authors.initials: J
authors.lastname: Bonastre
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin